IDH2 and glioma: Inhibitors of mutant IDH1 have been characterized, such as the recently FDA-approved Vorasidenib [93], a first-in-class dual inhibitor of mutant IDH1 and IDH2 [94] with proven efficacy in IDH-mutant gliomas.